A. Zanchi

Discipline

Psychologie (5) Education (2) Anthropologie sociale et ethnologie (1)

Type de document

Articles (27) Recensions (10)

Co-auteur

Date

Source

Mot-clé

Patients (20) Patients (16) Diabetes (15) Treatment (11) risque (10) Risk (10) Use (10) Human beings (9) maladie (9) thérapie (8) maladie (8) Control (8) Therapeutics (8) Non-insulin-dependent diabetes (8) Insulin (8) temps (durée) (7) Inhibitors (7) Time (7) Management (7) Management (7) effet (6) Care (6) Methods (6) Diseases (6) Diabetic nephropathies (6) Blood pressure (6) Methods (6) Will (5) Swiss (5) Sodium (5)

Documents écrit par A. Zanchi (27) | parle de A. Zanchi (0)

Néphropathie diabétique : soutenir l’adhésion médicamenteuse de façon interprofessionnelle [Diabetic nephropathy: Interprofessional support of medication adherence]
C. Bandiera et al. (31 mai 2023)
Diabetic kidney disease in type 2 diabetes: a consensus statement from the Swiss Societies of Diabetes and Nephrology.
A. Zanchi et al. (6 janv. 2023)
Understanding reasons and factors for participation and non-participation to a medication adherence program for patients with diabetic kidney disease in Switzerland: a mixed methods study.
C. Bandiera et al. (27 sept. 2022)
En quoi la prise en charge de l’hypertendu diabétique est-elle différente? [How is the management of diabetic hypertensive patients different?]
A. Dufey Teso et al. (14 sept. 2022)
Twenty-Four Hour Blood Pressure Response to Empagliflozin and Its Determinants in Normotensive Non-diabetic Subjects.
A. Zanchi et al. (2022)
Medication Adherence Evaluated Through Electronic Monitors During the 2020 COVID-19 Pandemic Lockdown in Switzerland: A Longitudinal Analysis.
C. Bandiera et al. (2022)
Antidiabétiques oraux et injectables pour le diabète de type 2 - Prise en charge multidisciplinaire du diabète : recommandations pour la pratique Clinique [Oral and injectable diabetes medications for type 2 diabetes - Multidisciplinary management of diabetes: Clinical practice guidelines]
C. Arditi et al. (23 juin 2021)
SGLT2 Inhibitors, What the Emergency Physician Needs to Know: A Narrative Review.
H. Lu et al. (10 mai 2021)
Inhibiteurs du SGLT2 dans les néphropathies diabétiques et non diabétiques [SGLT2 inhibitors in diabetic and non-diabetic nephropathies]
M. Scheen et al. (24 févr. 2021)
Assessing the efficacy and impact of a personalised smoking cessation intervention among type 2 diabetic smokers: study protocol for an open-label randomised controlled trial (DISCGO-RCT).
C. Clair et al. (19 nov. 2020)
Acute and Chronic Effects of SGLT2 Inhibitor Empagliflozin on Renal Oxygenation and Blood Pressure Control in Nondiabetic Normotensive Subjects: A Randomized, Placebo-Controlled Trial.
A. Zanchi et al. (7 juil. 2020)
Diabète post-transplantation rénale: le point de vue du diabétologue [Post-transplantation diabetes in kidney transplant: from the diabetologist point of view]
A. Pauchet et al. (10 juin 2020)
Adhésion thérapeutique et collaboration médecin-pharmacien. L’exemple du patient avec néphropathie diabétique [Medication adherence and physician-pharmacist collaboration. Focus on the patient with diabetic nephropathy]
M. Schneider et al. (10 juin 2020)
Diabète et infection à COVID-19 [Diabetes and COVID-19 infection]
C. Kosinski et al. (6 mai 2020)
Health status and quality of life in patients with diabetes in Switzerland.
C. Arditi et al.
Néphropathie diabétique - Prise en charge multidisciplinaire du diabète : recommandations pour la pratique clinique
C. Arditi et al. (17 avr. 2019)
Antidiabétiques oraux et injectablespour le diabète de type 2 - Prise en charge multidisciplinaire du diabète : recommandations pour la pratique clinique []
C. Arditi et al. (8 août 2018)
Effects of the SGLT-2 Inhibitor Empagliflozin on Renal Tissue Oxygenation in Non-Diabetic Subjects: A Randomized, Double-Blind, Placebo-Controlled Study Protocol.
M.E. Muller et al.
Changing trends in end-stage renal disease patients with diabetes.
Y. Lu et al. (11 juil. 2017)
Glycaemic, blood pressure and lipid goal attainment and chronic kidney disease stage of type 2 diabetic patients treated in primary care practices.
A. Corcillo et al. (11 juil. 2017)
The impact of a multidisciplinary self-care management program on quality of life, self-care, adherence to anti-hypertensive therapy, glycemic control, and renal function in diabetic kidney disease: A Cross-over Study Protocol.
N. Helou et al. (19 juil. 2016)
Chronic kidney disease in type 2 diabetic patients followed-up by primary care physicians in Switzerland: prevalence and prescription of antidiabetic drugs.
F. Lamine et al. (2016)
Pioglitazone improves fat distribution, the adipokine profile and hepatic insulin sensitivity in non-diabetic end-stage renal disease subjects on maintenance dialysis: a randomized cross-over pilot study.
A. Zanchi et al.
Long-term low-dose ketoconazole treatment in bilateral macronodular adrenal hyperplasia
S. Comte-Perret et al. (2014)
Antidiabetic drugs and kidney disease - Recommendations of the Swiss Society for Endocrinology and Diabetology.
A. Zanchi et al. (2012)

next